The Arkansas legislature on Tuesday passed what is believed to be the first bill nationally to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by contract pharmacies.
The state Senate passed the bipartisan bill,
President Biden has left out of his American Families human-capital investment plan drug pricing reforms that Democratic leaders in Congress have pressed him hard to add. House Speaker Nancy Pelosi (D-Calif.), House Energy and Commerce (E&C) Chair Frank Pallone (D-N.J.),
…SPONSORED CONTENT by Ross Halsne
It’s becoming increasingly difficult for Covered Entities (CEs) to effectively manage their 340B pharmacy programs. Often times understaffed relative to the task of handling the myriad of challenges that come with managing a 340B program, they face a seemingly constant barrage of maneuvering and attacks aimed at reducing their 340B benefit. In response, many Covered Entities are evaluating new strategies to strengthen or reinvigorate their program. If your Covered Entity is taking a fresh
…
A federal judge in Delaware yesterday declined to add hospital groups as third parties to a drugmaker’s lawsuit challenging the federal government’s 340B program contract pharmacy enforcement mechanisms. But he left the door open to letting the groups participate as
…
President Biden might exclude legislation to reduce what consumers and the federal government pay for prescription drugs from his American Families human and capital investment initiative, news organizations report this morning. Biden is scheduled to describe his infrastructure investment plan
…
A federal district judge in Wilmington, Del., ruled this morning that six hospital groups cannot participate as third parties in drug manufacturer AstraZeneca’s lawsuit against the government over its 340B contract pharmacy requirements.
In a ruling delivered from the bench,
…
UPDATE Thursday, April 22, 2021, 1:00 p.m. EDT—U.S. House Energy and Commerce (E&C) Chair Frank Pallone this morning introduced a significantly slimmed-down version of H.R. 3, the drug pricing bill that the House passed during the last session of Congress
…*Sign up for news summaries and alerts from 340B Report
